CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Phase 2
94
about 7 years
18+
1 site in IL
About this study
This trial is testing a treatment with CPI-613, hydroxychloroquine, and either 5-fluorouracil or gemcitabine for advanced solid tumors that have not responded to chemotherapy. The goal is to see if this combination can help slow the growth of these tumors.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Devimistat
- 2.Take Fluorouracil
- 3.Take Gemcitabine Hydrochloride
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
fluorouracil (Antimetabolite; mimics uracil to disrupt DNA/RNA in cancer cells), Antineoplastic Agent [TC] (Nucleic Acid Synthesis Inhibitors), hydroxychloroquine (Antimalarial; increases pH in parasite)
oral (Oral Capsule), oral
Primary: Overall response rate (ORR)
Secondary: Duration of response (DOR), Incidence of adverse events, Overall survival (OS), Progression free survival (PFS)
diagnostic, imaging
Oncology, Respiratory